(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Bed Bath & Beyond, FIRST REPUBLIC BANK, and Intuitive Surgical.

Rank	Financial Asset	Price	Change	Updated (EST)
1	Bed Bath & Beyond (BBBY)	0.34	22.46%	2023-04-19 03:15:07
2	FIRST REPUBLIC BANK (FRC)	14.37	14.21%	2023-04-19 13:33:34
3	Intuitive Surgical (ISRG)	300.04	11.42%	2023-04-19 13:25:39
4	Abbott Laboratories (ABT)	112.29	7.82%	2023-04-19 13:31:08
5	Abraxas Petroleum Corporation (AXAS)	0.72	7.46%	2023-04-19 02:23:07
6	Auburn National Bancorporation (AUBN)	23.75	7.42%	2023-04-19 01:15:07
7	Ascent Solar Technologies (ASTI)	0.38	7.41%	2023-04-18 23:23:07
8	The Travelers Companies (TRV)	183.24	6.53%	2023-04-19 13:45:26
9	United Airlines (UAL)	45.78	6.37%	2023-04-19 13:30:38
10	Altisource Portfolio Solutions S.A. (ASPS)	4.07	5.99%	2023-04-18 23:11:07

The three biggest losers today are Calithera Biosciences, CDW Corporation, and Athersys.

Rank	Financial Asset	Price	Change	Updated (EST)
1	Calithera Biosciences (CALA)	0.04	-23.08%	2023-04-19 11:15:08
2	CDW Corporation (CDW)	165.46	-13.05%	2023-04-19 13:23:14
3	Athersys (ATHX)	0.99	-11.33%	2023-04-19 00:23:08
4	Bellicum Pharmaceuticals (BLCM)	0.52	-9.46%	2023-04-19 07:11:07
5	Accelerate Diagnostics (AXDX)	0.68	-9.33%	2023-04-19 03:06:07
6	Riot Blockchain (RIOT)	12.32	-8.4%	2023-04-19 13:30:06
7	Xenetic Biosciences (XBIO)	0.43	-7.83%	2023-04-19 13:15:31
8	Nikola (NKLA)	0.90	-7.68%	2023-04-19 13:14:28
9	Central Garden & Pet Company (CENT)	37.05	-7.44%	2023-04-19 15:49:08
10	Central Garden & Pet Company (CENTA)	35.35	-7.12%	2023-04-19 16:17:07

Winners today

1. Bed Bath & Beyond (BBBY) – 22.46%

Bed Bath & Beyond Inc., together with its subsidiaries, operates a chain of retail stores. It sells a range of domestics merchandise, including bed linens and related items, bath items, and kitchen textiles; and home furnishings, such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings, consumables, and various juvenile products. As of February 26, 2022, the company had 953 stores, which included 771 Bed Bath & Beyond stores in 50 states, the District of Columbia, Puerto Rico, and Canada; 130 buybuy BABY stores in 37 states and Canada; and 52 stores in 6 states under the names Harmon, Harmon Face Values or Face Values. It also offers products through various Websites and applications comprising bedbathandbeyond.com, bedbathandbeyond.ca, harmondiscount.com, facevalues.com, buybuybaby.com, buybuybaby.ca, and decorist.com. In addition, the company operates Decorist, an online interior design platform that provides personalized home design services. Bed Bath & Beyond Inc. was incorporated in 1971 and is headquartered in Union, New Jersey.

NASDAQ ended the session with Bed Bath & Beyond rising 22.46% to $0.34 on Wednesday while NASDAQ jumped 0.03% to $12,157.23.

Earnings Per Share

As for profitability, Bed Bath & Beyond has a trailing twelve months EPS of $-17.81.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 81.5% and positive 49.8% for the next.

Yearly Top and Bottom Value

Bed Bath & Beyond’s stock is valued at $0.34 at 17:32 EST, way under its 52-week high of $30.00 and way above its 52-week low of $0.23.

Sales Growth

Bed Bath & Beyond’s sales growth is negative 32.5% for the current quarter and negative 21.6% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Bed Bath & Beyond’s EBITDA is -14.18.

More news about Bed Bath & Beyond.

2. FIRST REPUBLIC BANK (FRC) – 14.21%

First Republic Bank, together with its subsidiaries, provides private banking, private business banking, and private wealth management services to clients in metropolitan areas in the United States. It operates in two segments, Commercial Banking and Wealth Management. The company accepts deposit products, such as noninterest-bearing checking, interest-bearing checking, money market checking accounts, money market savings accounts, and passbook accounts, as well as certificates of deposit. It also offers a range of lending products that comprise residential mortgage loans, home equity lines of credit, multifamily loans, commercial real estate and construction loans, personal and business loans, single family construction loans, and other loans and lines of credit to businesses and individuals. The company's loans are secured by single family residences, multifamily buildings, and commercial real estate properties. In addition, it provides wealth management services, which include various investment strategies and products, online investment management, trust and custody, full service and online brokerage, financial and estate planning, and access to alternative investments, as well as investing, insurance, and foreign exchange services. Further, the company offers online and mobile banking services; refinancing services; and ATM and debit cards. First Republic Bank was founded in 1985 and is headquartered in San Francisco, California.

NYSE ended the session with FIRST REPUBLIC BANK jumping 14.21% to $14.37 on Wednesday while NYSE dropped 0.2% to $15,653.62.

Earnings Per Share

As for profitability, FIRST REPUBLIC BANK has a trailing twelve months EPS of $8.25.

PE Ratio

FIRST REPUBLIC BANK has a trailing twelve months price to earnings ratio of 1.74. Meaning, the purchaser of the share is investing $1.74 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.99%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 57.5% and a negative 102.3%, respectively.

More news about FIRST REPUBLIC BANK.

3. Intuitive Surgical (ISRG) – 11.42%

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

NASDAQ ended the session with Intuitive Surgical rising 11.42% to $300.04 on Wednesday, after four successive sessions in a row of gains. NASDAQ rose 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Intuitive Surgical has a trailing twelve months EPS of $3.66.

PE Ratio

Intuitive Surgical has a trailing twelve months price to earnings ratio of 81.98. Meaning, the purchaser of the share is investing $81.98 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.66%.

Sales Growth

Intuitive Surgical’s sales growth is 7.2% for the current quarter and 11.8% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Intuitive Surgical’s stock is considered to be oversold (<=20).

Volatility

Intuitive Surgical’s last week, last month’s, and last quarter’s current intraday variation average was 0.71%, 0.69%, and 1.46%.

Intuitive Surgical’s highest amplitude of average volatility was 0.71% (last week), 1.16% (last month), and 1.46% (last quarter).

Previous days news about Intuitive Surgical

Is intuitive surgical (isrg) A buy ahead of Q1 earnings announcement?. According to Zacks on Tuesday, 18 April, "Well-known medical instruments company Intuitive Surgical (ISRG Quick QuoteISRG – Free Report) is set to report first-quarter earnings results on Tuesday after the close. "

More news about Intuitive Surgical.

4. Abbott Laboratories (ABT) – 7.82%

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

NYSE ended the session with Abbott Laboratories rising 7.82% to $112.29 on Wednesday while NYSE slid 0.2% to $15,653.62.

Earnings Per Share

As for profitability, Abbott Laboratories has a trailing twelve months EPS of $3.91.

PE Ratio

Abbott Laboratories has a trailing twelve months price to earnings ratio of 28.72. Meaning, the purchaser of the share is investing $28.72 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.01%.

Sales Growth

Abbott Laboratories’s sales growth is negative 19% for the current quarter and negative 12.6% for the next.

Volume

Today’s last reported volume for Abbott Laboratories is 8543440 which is 62.82% above its average volume of 5246910.

Volatility

Abbott Laboratories’s last week, last month’s, and last quarter’s current intraday variation average was 0.39%, 0.44%, and 1.05%.

Abbott Laboratories’s highest amplitude of average volatility was 0.57% (last week), 0.84% (last month), and 1.05% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 12%, now sitting on 43.65B for the twelve trailing months.

More news about Abbott Laboratories.

5. Abraxas Petroleum Corporation (AXAS) – 7.46%

Abraxas Petroleum Corporation, an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of oil and gas properties in the United States. The company operates oil and gas assets in the Permian/Delaware Basin and the Rocky Mountain regions. As of December 31, 2021, its estimated net proved reserves were 14.8 million barrels of oil equivalent. The company was founded in 1977 and is based in San Antonio, Texas.

NASDAQ ended the session with Abraxas Petroleum Corporation jumping 7.46% to $0.72 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ jumped 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Abraxas Petroleum Corporation has a trailing twelve months EPS of $4.19.

PE Ratio

Abraxas Petroleum Corporation has a trailing twelve months price to earnings ratio of 0.17. Meaning, the purchaser of the share is investing $0.17 for every dollar of annual earnings.

More news about Abraxas Petroleum Corporation.

6. Auburn National Bancorporation (AUBN) – 7.42%

Auburn National Bancorporation, Inc. operates as the bank holding company for AuburnBank that provides various banking products and services in East Alabama. The company's deposit products include checking, savings, and transaction deposit accounts, as well as certificates of deposit. It also provides commercial, financial, agricultural, real estate construction, and consumer loan products; and other financial services. In addition, the company offers automated teller services; debit cards; online banking, bill payment, and other electronic services; and safe deposit boxes. It operates through seven full-service branches in Auburn, Opelika, Notasulga, and Valley, Alabama; as well as loan production offices in Auburn and Phenix City, Alabama. Auburn National Bancorporation, Inc. was founded in 1907 and is headquartered in Auburn, Alabama.

NASDAQ ended the session with Auburn National Bancorporation jumping 7.42% to $23.75 on Wednesday while NASDAQ rose 0.03% to $12,157.23.

Earnings Per Share

As for profitability, Auburn National Bancorporation has a trailing twelve months EPS of $2.95.

PE Ratio

Auburn National Bancorporation has a trailing twelve months price to earnings ratio of 8.05. Meaning, the purchaser of the share is investing $8.05 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.05%.

Moving Average

Auburn National Bancorporation’s worth is higher than its 50-day moving average of $23.71 and under its 200-day moving average of $24.43.

Volume

Today’s last reported volume for Auburn National Bancorporation is 504 which is 60.37% below its average volume of 1272.

Revenue Growth

Year-on-year quarterly revenue growth grew by 47.3%, now sitting on 32.67M for the twelve trailing months.

More news about Auburn National Bancorporation.

7. Ascent Solar Technologies (ASTI) – 7.41%

Ascent Solar Technologies, Inc. designs, manufactures, and sells copper-indium-gallium-diselenide photovoltaic products for aerospace, defense, emergency management, and consumer/OEM applications. It offers outdoor solar chargers. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies. Ascent Solar Technologies, Inc. was incorporated in 2005 and is based in Thornton, Colorado.

NASDAQ ended the session with Ascent Solar Technologies rising 7.41% to $0.38 on Wednesday while NASDAQ jumped 0.03% to $12,157.23.

Earnings Per Share

As for profitability, Ascent Solar Technologies has a trailing twelve months EPS of $-0.65.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2255.19%.

Yearly Top and Bottom Value

Ascent Solar Technologies’s stock is valued at $0.38 at 17:32 EST, way below its 52-week high of $11.50 and way higher than its 52-week low of $0.33.

Moving Average

Ascent Solar Technologies’s worth is way under its 50-day moving average of $0.52 and way below its 200-day moving average of $2.50.

More news about Ascent Solar Technologies.

8. The Travelers Companies (TRV) – 6.53%

The Travelers Companies, Inc., through its subsidiaries, provides a range of commercial and personal property, and casualty insurance products and services to businesses, government units, associations, and individuals in the United States and internationally. It operates through three segments: Business Insurance, Bond & Specialty Insurance, and Personal Insurance. The Business Insurance segment offers workers' compensation, commercial automobile and property, general liability, commercial multi-peril, employers' liability, public and product liability, professional indemnity, marine, aviation, onshore and offshore energy, construction, terrorism, personal accident, and kidnap and ransom insurance products. This segment operates through select accounts, which serve small businesses; commercial accounts that serve mid-sized businesses; national accounts, which serve large companies; and national property and other that serve large and mid-sized customers, commercial trucking industry, and agricultural businesses, as well as markets and distributes its products through brokers, wholesale agents, and program managers. The Bond & Specialty Insurance segment provides surety, fidelity, management and professional liability, and other property and casualty coverages and related risk management services through independent agencies and brokers. The Personal Insurance segment offers property and casualty insurance covering personal risks, primarily automobile and homeowners' insurance to individuals through independent agencies and brokers. The Travelers Companies, Inc. was founded in 1853 and is based in New York, New York.

NYSE ended the session with The Travelers Companies jumping 6.53% to $183.24 on Wednesday, after two sequential sessions in a row of gains. NYSE fell 0.2% to $15,653.62, after two sequential sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, The Travelers Companies has a trailing twelve months EPS of $11.76.

PE Ratio

The Travelers Companies has a trailing twelve months price to earnings ratio of 15.58. Meaning, the purchaser of the share is investing $15.58 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.27%.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 8, 2023, the estimated forward annual dividend rate is 3.72 and the estimated forward annual dividend yield is 2.21%.

Yearly Top and Bottom Value

The Travelers Companies’s stock is valued at $183.24 at 17:32 EST, below its 52-week high of $194.51 and way higher than its 52-week low of $149.65.

Sales Growth

The Travelers Companies’s sales growth is 9.8% for the ongoing quarter and 9.2% for the next.

More news about The Travelers Companies.

9. United Airlines (UAL) – 6.37%

United Airlines Holdings, Inc., through its subsidiaries, provides air transportation services in North America, Asia, Europe, Africa, the Pacific, the Middle East, and Latin America. The company transports people and cargo through its mainline and regional fleets. It also offers catering, ground handling, training, and maintenance services for third parties. The company was formerly known as United Continental Holdings, Inc. and changed its name to United Airlines Holdings, Inc. in June 2019. United Airlines Holdings, Inc. was incorporated in 1968 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with United Airlines jumping 6.37% to $45.78 on Wednesday, after two successive sessions in a row of gains. NASDAQ jumped 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

United Airlines (ual) incurs loss in Q1, beats revenue estimatesUnited Airlines Holdings Inc price-consensus-eps-surprise-chart | United Airlines Holdings Inc Quote, For the second quarter of 2023, United Airlines expects capacity to improve by almost 18.5% from the year-ago reported figure.

Earnings Per Share

As for profitability, United Airlines has a trailing twelve months EPS of $2.27.

PE Ratio

United Airlines has a trailing twelve months price to earnings ratio of 20.17. Meaning, the purchaser of the share is investing $20.17 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.36%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, United Airlines’s stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

United Airlines’s stock is valued at $45.78 at 17:32 EST, way under its 52-week high of $55.04 and way above its 52-week low of $31.58.

Moving Average

United Airlines’s value is under its 50-day moving average of $47.23 and above its 200-day moving average of $41.81.

More news about United Airlines.

10. Altisource Portfolio Solutions S.A. (ASPS) – 5.99%

Altisource Portfolio Solutions S.A. operates as an integrated service provider and marketplace for the real estate and mortgage industries in the United States, India, Luxembourg, Uruguay, and internationally. It provides property preservation and inspection services, payment management technologies, and a vendor management oversight software-as-a-service (SaaS) platform. The company also offers Hubzu, an online real estate auction platform, as well as real estate auction, real estate brokerage, and asset management services; and Equator, a SaaS-based technology to manage real estate owned, short sales, foreclosure, bankruptcy, and eviction processes. In addition, it provides mortgage loan fulfillment, certification and certification insurance services, technologies, title insurance agent, settlement, real estate valuation services, residential and commercial construction inspection and risk mitigation, foreclosure trustee, and commercial loan servicing technology services. Further, the company operates TrelixTM Connect, Vendorly, RentRange, REALSynergy, Lenders One Loan Automation, and other platform solutions. It serves financial institutions, government-sponsored enterprises, banks, asset managers, servicers, investors, originators, correspondent lenders, and mortgage bankers. Altisource Portfolio Solutions S.A. was incorporated in 1999 and is headquartered in Luxembourg City, Luxembourg.

NASDAQ ended the session with Altisource Portfolio Solutions S.A. jumping 5.99% to $4.07 on Wednesday, following the last session’s upward trend. NASDAQ rose 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Altisource Portfolio Solutions S.A. has a trailing twelve months EPS of $-3.32.

More news about Altisource Portfolio Solutions S.A..

Losers Today

1. Calithera Biosciences (CALA) – -23.08%

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Calithera Biosciences dropping 23.08% to $0.04 on Wednesday while NASDAQ jumped 0.03% to $12,157.23.

Earnings Per Share

As for profitability, Calithera Biosciences has a trailing twelve months EPS of $-7.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -114.14%.

Yearly Top and Bottom Value

Calithera Biosciences’s stock is valued at $0.04 at 17:32 EST, below its 52-week low of $0.04.

Moving Average

Calithera Biosciences’s value is way below its 50-day moving average of $0.06 and way under its 200-day moving average of $1.93.

More news about Calithera Biosciences.

2. CDW Corporation (CDW) – -13.05%

CDW Corporation provides information technology (IT) solutions in the United States, the United Kingdom, and Canada. It operates through three segments: Corporate, Small Business, and Public. The company offers discrete hardware and software products and services, as well as integrated IT solutions, including on-premise, hybrid, and cloud capabilities across hybrid infrastructure, digital experience, and security. Its hardware products comprise notebooks/mobile devices, network communications, desktop computers, video monitors, enterprise and data storage, and others; and software products consists of application suites, security, virtualization, operating systems, and network management. The company also provides advisory and design, software development, implementation, managed, professional, configuration, partner, and telecom services, as well as warranties; delivers and manages mission critical software, systems, and network solutions; and implementation and installation, and repair services to its customers through various third-party service providers. It serves government, education, and healthcare customers; and small, medium, and large business customers. CDW Corporation was founded in 1984 and is headquartered in Vernon Hills, Illinois.

NASDAQ ended the session with CDW Corporation falling 13.05% to $165.46 on Wednesday while NASDAQ rose 0.03% to $12,157.23.

Earnings Per Share

As for profitability, CDW Corporation has a trailing twelve months EPS of $8.13.

PE Ratio

CDW Corporation has a trailing twelve months price to earnings ratio of 20.35. Meaning, the purchaser of the share is investing $20.35 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 96.54%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

CDW Corporation’s EBITDA is 69.37.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CDW Corporation’s stock is considered to be oversold (<=20).

Sales Growth

CDW Corporation’s sales growth is negative 6.5% for the ongoing quarter and negative 3.1% for the next.

More news about CDW Corporation.

3. Athersys (ATHX) – -11.33%

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

NASDAQ ended the session with Athersys falling 11.33% to $0.99 on Wednesday while NASDAQ jumped 0.03% to $12,157.23.

Earnings Per Share

As for profitability, Athersys has a trailing twelve months EPS of $-7.23.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Athersys’s EBITDA is -0.7.

Yearly Top and Bottom Value

Athersys’s stock is valued at $0.99 at 17:32 EST, way below its 52-week high of $19.50 and way above its 52-week low of $0.50.

More news about Athersys.

4. Bellicum Pharmaceuticals (BLCM) – -9.46%

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

NASDAQ ended the session with Bellicum Pharmaceuticals dropping 9.46% to $0.52 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Bellicum Pharmaceuticals has a trailing twelve months EPS of $-1.59.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -79.94%.

Volume

Today’s last reported volume for Bellicum Pharmaceuticals is 3746090 which is 279.79% above its average volume of 986347.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 36% and positive 30.8% for the next.

More news about Bellicum Pharmaceuticals.

5. Accelerate Diagnostics (AXDX) – -9.33%

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

NASDAQ ended the session with Accelerate Diagnostics dropping 9.33% to $0.68 on Wednesday while NASDAQ rose 0.03% to $12,157.23.

Earnings Per Share

As for profitability, Accelerate Diagnostics has a trailing twelve months EPS of $-0.86.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 33.3% and 56.5%, respectively.

More news about Accelerate Diagnostics.

6. Riot Blockchain (RIOT) – -8.4%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain sliding 8.4% to $12.32 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-3.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.77%.

Sales Growth

Riot Blockchain’s sales growth is negative 5.3% for the current quarter and 20.3% for the next.

Yearly Top and Bottom Value

Riot Blockchain’s stock is valued at $12.32 at 17:32 EST, way under its 52-week high of $15.21 and way higher than its 52-week low of $3.25.

Revenue Growth

Year-on-year quarterly revenue growth declined by 33.8%, now sitting on 259.17M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Riot Blockchain’s EBITDA is -11.83.

More news about Riot Blockchain.

7. Xenetic Biosciences (XBIO) – -7.83%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences falling 7.83% to $0.43 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-0.45.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.9%.

Moving Average

Xenetic Biosciences’s worth is way under its 50-day moving average of $0.49 and way under its 200-day moving average of $0.57.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Xenetic Biosciences’s EBITDA is 6.09.

Volatility

Xenetic Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.33%, a negative 0.14%, and a positive 4.86%.

Xenetic Biosciences’s highest amplitude of average volatility was 4.78% (last week), 3.89% (last month), and 4.86% (last quarter).

More news about Xenetic Biosciences.

8. Nikola (NKLA) – -7.68%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola sliding 7.68% to $0.90 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ jumped 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-2.12.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -128.56%.

Yearly Top and Bottom Value

Nikola’s stock is valued at $0.90 at 17:32 EST, way below its 52-week high of $8.97 and way above its 52-week low of $0.81.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 23.8% and positive 12% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikola’s stock is considered to be oversold (<=20).

Sales Growth

Nikola’s sales growth is 563% for the present quarter and 16.2% for the next.

More news about Nikola.

9. Central Garden & Pet Company (CENT) – -7.44%

Central Garden & Pet Company produces and distributes various products for the lawn and garden, and pet supplies markets in the United States. It operates through two segments, Pet and Garden. The Pet segment provides dog and cat supplies, such as dog treats and chews, toys, pet beds and grooming products, waste management and training pads, and pet containment; supplies for aquatics, small animals, reptiles, and pet birds, including toys, cages and habitats, bedding, and food and supplements; animal and household health and insect control products; live fish and products for fish, reptiles, and other aquarium-based pets, such as aquariums, furniture and lighting fixtures, pumps, filters, water conditioners, food, and supplements; and products for equine and livestock, as well as outdoor cushions. This segment sells its products under the Aqueon, Cadet, Comfort Zone, Farnam, Four Paws, Kaytee, K&H Pet Products, Nylabone, and Zilla brands. The Garden segment offers lawn and garden supplies products that include grass seed; vegetable; flower and herb packet seed; wild bird feed, bird feeders, bird houses, and other birding accessories; fertilizers; decorative outdoor lifestyle products; live plants; and weed and grass, as well as other herbicides, insecticide, and pesticide products. This segment sells its lawn and garden supplies products under the AMDRO, Ferry-Morse, IMAGE, and Sevin brands, as well as under Bell Nursery, Lilly Miller, and Over-N-Out other brand names. Central Garden & Pet Company was founded in 1955 and is based in Walnut Creek, California.

NASDAQ ended the session with Central Garden & Pet Company sliding 7.44% to $37.05 on Wednesday while NASDAQ jumped 0.03% to $12,157.23.

Earnings Per Share

As for profitability, Central Garden & Pet Company has a trailing twelve months EPS of $2.46.

PE Ratio

Central Garden & Pet Company has a trailing twelve months price to earnings ratio of 15.06. Meaning, the purchaser of the share is investing $15.06 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.55%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Central Garden & Pet Company’s EBITDA is 129.05.

Revenue Growth

Year-on-year quarterly revenue growth declined by 5.1%, now sitting on 3.3B for the twelve trailing months.

Yearly Top and Bottom Value

Central Garden & Pet Company’s stock is valued at $37.05 at 17:32 EST, way below its 52-week high of $46.78 and higher than its 52-week low of $35.61.

More news about Central Garden & Pet Company.

10. Central Garden & Pet Company (CENTA) – -7.12%

NASDAQ ended the session with Central Garden & Pet Company dropping 7.12% to $35.35 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.03% to $12,157.23, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Central Garden & Pet Company has a trailing twelve months EPS of $2.45.

PE Ratio

Central Garden & Pet Company has a trailing twelve months price to earnings ratio of 14.43. Meaning, the purchaser of the share is investing $14.43 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.55%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Central Garden & Pet Company’s EBITDA is 129.05.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 26% and positive 6.5% for the next.

More news about Central Garden & Pet Company.

Stay up to date with our winners and losers daily report